

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (hi-181)

NAVAFENTEROL SACCHARINATE

PRONUNCIATION

nav" a fen' ter ol


THERAPEUTIC CLAIM

Maintenance treatment of patients with obstructive airways diseases (Chronic Obstructive Pulmonary Disease (COPD) or Asthma)

CHEMICAL NAMES

1. 2-Thiopheneacetic acid, α -hydroxy- α -2-thienyl-, trans-4-[[3-[5-[[[(2*R*)-2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]methyl]-1*H*-benzotriazol-1-yl]propyl]methylamino]cyclohexyl ester, compd. with 1,2-benzisothiazol-3(2*H*)-one 1,1-dioxide (1:1)
2. trans-4-[[3-[5-[[[(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino]methyl]-1*H*-1,2,3- benzotriazol-1-yl]propyl](methyl)amino]cyclohexyl hydroxydi(thiophen-2-yl)acetate, benzo[d]isothiazol-3(2*H*)-one 1,1-dioxide (1:1)

STRUCTURAL FORMULA



MOLECULAR FORMULA

$C_{38}H_{42}N_6O_6S_2 \cdot C_7H_5NO_3S$

MOLECULAR WEIGHT

926.1 Da

TRADEMARK

None as yet

SPONSOR

AstraZeneca

CODE DESIGNATIONS

None

CAS REGISTRY NUMBER

1648550-37-1

UNII

3K9GRC4RNX

bww